Cirrhosis, Hypotension
Conditions
Brief summary
Cirrhosis is an end stage in liver disease leading to replacement of normal liver tissue with regenerative nodules surrounded by fibrous bands in response to chronic liver injury. It is the eighth leading cause of death in the United States and the thirteenth leading cause of death globally. Patients with cirrhosis have decreased spontaneous vascular resistance leading to hypotension. The mechanism of hypotension in cirrhosis is thought to be a complex result of the presence of increased level of circulating vasodilators such a nitric oxide coupled with reduced resistance to vasoconstrictors and increased sensitivity to vasodilators.
Detailed description
Another potential contributor to the development of hypotension in cirrhosis is thought to be due to the increased production of estrogen in males especially the estrone (E1) and estradiol (E2) concentration. The concentration of estrogen in cirrhotic patients is thought to increase by fourfold compared to individuals without cirrhosis. The increased estrogen concentration in cirrhosis patients results, in large part, from an increased peripheral conversion from androgens including testosterone. Previous studies have shown that increased estrogen concentration can cause a significant decrease in blood pressure in various cell, animal, and human models. Of note, estrogen has also been shown to enhance nitric oxide production in human beings.
Interventions
To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
Sponsors
Study design
Eligibility
Inclusion criteria
* Male cirrhotic patients \>18 years of age * Patient must attend the outpatient clinic of the Liver Institute at Methodist Dallas Medical Center * willing to provide informed consent to participate in the study
Exclusion criteria
* Patients with a history of cirrhosis \<18 years of age * Cirrhosis patients with active infection * Cirrhosis patients with active gastrointestinal bleeding * Cirrhosis patients on hormone replacement therapy testosterone * Cirrhosis patients on any antihypertensive medications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum estrogen (E1 and E2) levels | July to September 2021 | Measurement of serum estrogen (E1 and E2) levels in cirrhotic males |
| Serum testosterone levels | July to September 2021 | Measurement of serum testosterone levels in cirrhotic males |
Contacts
Methodist